Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.71 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.71 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.57 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.57 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.56 |
| ▸ | PPARG | P37231 | 7/20 | 0.55 |
| ▸ | PPARD | Q03181 | 7/20 | 0.55 |
| ▸ | PPARA | Q07869 | 7/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.55 |
| ▸ | TLR2 | O60603 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | FABP4 | P15090 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4534190 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL4528754 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL931159 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL401025 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL4530530 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL6887374 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL4525726 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL4518788 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL4529944 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL4523441 | 1.00 | TSHR (0.71) | TSHRLMNANFKB1PMP22GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092078-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | DECIDUOUS THERAPEUTICS, INC. (US) | 2025-03-20 | — | — | US | disclosed |
| US-12037357-B2 | Compounds for activating invariant natural killer T-cells and methods of use in eliminating inflammatory senescent cells | DECIDUOUS THERAPEUTICS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240025936-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | DECIDUOUS THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | US | disclosed |
| EP-4301374-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | Deciduous Therapeutics, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-117222414-A | Compounds for activating constant natural killer T-cells and methods for eliminating inflammatory senescent cells | 脱落性治疗公司 | 2023-12-12 | — | — | CN | disclosed |
| WO-2022187141-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | DECIDUOUS THERAPEUTICS (US) | 2022-09-09 | — | — | WO | disclosed |
| US-20090123516-A1 | DRUG DELIVERY FROM IMPLANTS USING SELF-ASSEMBLED MONOLAYERS-THERAPEUTIC SAMS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2009-05-14 | — | — | US | disclosed |
| WO-2007019478-A2 | DRUG DELIVERY FROM IMPLANTS USING SELF-ASSEMBLED MONOLAYERS - THERAPEUTIC SAMS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037357-B2 | Compounds for activating invariant natural killer T-cells and methods of use in eliminating inflammatory senescent cells | IL2, IL4, PBK | TSHR 3328/4885LMNA 990/4885NFKB1 131/4885 |
| US-20240025936-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | IL2, PBK, IL4 | TSHR 3553/4885LMNA 893/4885NFKB1 243/4885 |
| US-20250092078-A1 | COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T-CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS | IL2, PBK, IL4 | TSHR 3503/4885LMNA 945/4885NFKB1 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.